Your browser doesn't support javascript.
loading
Public Health Clinic-Based Hepatitis C Treatment.
Rosecrans, Amanda M; Cheedalla, Aneesha; Rives, Sarah T; Scotti, Lisa A; Harris, Robert E; Greenbaum, Adena H; Irvin, Risha R; Ntiri-Reid, Boatemaa A; Brown, Holly T; Alston, Karen E; Smith, Jaeson A; Page, Kathleen R; Falade-Nwulia, Oluwaseun O.
Afiliación
  • Rosecrans AM; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland. Electronic address: amanda.rosecrans@baltimorecity.gov.
  • Cheedalla A; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Rives ST; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland.
  • Scotti LA; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland.
  • Harris RE; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland.
  • Greenbaum AH; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland.
  • Irvin RR; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Ntiri-Reid BA; Prevention and Health Promotion Administration, Maryland Department of Health, Baltimore, Maryland.
  • Brown HT; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland.
  • Alston KE; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland.
  • Smith JA; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland.
  • Page KR; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Population Health and Disease Prevention, Baltimore City Health Department, Baltimore, Maryland.
  • Falade-Nwulia OO; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Am J Prev Med ; 59(3): 420-427, 2020 09.
Article en En | MEDLINE | ID: mdl-32430222
INTRODUCTION: The availability of safe, effective treatments for hepatitis C virus infection has led to a call for the elimination of hepatitis C, but barriers to care persist. METHODS: In July 2015, the Baltimore City Health Department sexual health clinics began on-site hepatitis C virus treatment. Investigators conducted a retrospective evaluation of the first 2.5 years of this program. Data were extracted from the medical record through June 2019, and data analysis was completed in September 2019. RESULTS: Between July 2015 and December 2017, a total of 560 patients infected with hepatitis C virus accessed care at the Baltimore City Health Department sexual health clinics. Of these patients, 423 (75.5%) were scheduled for hepatitis C virus evaluation at the clinics, 347 (62.0%) attended their evaluation appointment, 266 (47.5%) were prescribed treatment, 227 (40.5%) initiated treatment, and 199 (35.5%) achieved sustained virologic response. Older age was independently associated with hepatitis C virus evaluation appointment attendance (aged 40-59 years: AOR=3.64, 95% CI=1.88, 7.06; aged ≥60 years: AOR=5.61, 95% CI=2.58, 12.21) compared with those aged 20-39 years. Among those who attended hepatitis C virus evaluation appointments, advanced liver disease was independently and positively associated with treatment initiation (AOR=11.89, 95% CI=6.35, 22.25). Conversely, illicit substance use in the past 12 months was negatively associated with hepatitis C virus treatment initiation (AOR=0.49, 95% CI=0.25, 0.96). CONCLUSIONS: The integration of hepatitis C virus testing and on-site treatment in public sexual health clinics is an innovative approach to improve access to hepatitis C virus treatment for medically underserved populations.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Salud Pública / Hepatitis C Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Am J Prev Med Asunto de la revista: SAUDE PUBLICA Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Salud Pública / Hepatitis C Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Am J Prev Med Asunto de la revista: SAUDE PUBLICA Año: 2020 Tipo del documento: Article